. . . . "[D2867211DC95]" . . "Randomizovan\u00E9, 2x zaslepen\u00E9, placebem kontrolovan\u00E9 klinick\u00E9 hodnocen\u00ED s paraleln\u00EDmi skupinami a s otev\u0159enou roz\u0161i\u0159uj\u00EDc\u00ED f\u00E1z\u00ED pro posouzen\u00ED \u00FA\u010Dinku perampanelu (E2007"@cs . "Randomizovan\u00E9, 2x zaslepen\u00E9, placebem kontrolovan\u00E9 klinick\u00E9 hodnocen\u00ED s paraleln\u00EDmi skupinami a s otev\u0159enou roz\u0161i\u0159uj\u00EDc\u00ED f\u00E1z\u00ED pro posouzen\u00ED \u00FA\u010Dinku perampanelu (E2007"@cs . "Randomizovan\u00E9, 2x zaslepen\u00E9, placebem kontrolovan\u00E9 klinick\u00E9 hodnocen\u00ED s paraleln\u00EDmi skupinami a s otev\u0159enou roz\u0161i\u0159uj\u00EDc\u00ED f\u00E1z\u00ED pro posouzen\u00ED \u00FA\u010Dinku perampanelu (E2007" . "Randomizovan\u00E9, 2x zaslepen\u00E9, placebem kontrolovan\u00E9 klinick\u00E9 hodnocen\u00ED s paraleln\u00EDmi skupinami a s otev\u0159enou roz\u0161i\u0159uj\u00EDc\u00ED f\u00E1z\u00ED pro posouzen\u00ED \u00FA\u010Dinku perampanelu (E2007" . . "24"^^ . "1"^^ . . . . "N" . "A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizure"@en . . "PPD Czech Republic, s.r.o." . "Hada\u010D, Jan" . "101442" . "Praha" . "RIV/00064190:_____/13:#0000734" . . "The primary objective is to evaluate the efficacy of 3 doses of perampanel (2 mg, 4 mg, and 8 mg) in comparison to placebo given as an adjunctive therapy in subjects with refractory partial seizures. The secondary objective is to evaluate the safety and tolerability of perampanel vs. placebo in subjects with refractory partial seizures."@en . . "1"^^ . "RIV/00064190:_____/13:#0000734!RIV14-MZ0-00064190" . "Hlavn\u00EDm c\u00EDlem klinick\u00E9 studie je zhodnotit \u00FA\u010Dinnost 3 d\u00E1vek perampanel (2 mg, 4 mg a 8 mg) ve srovn\u00E1n\u00ED s placebem dan\u00FD jako podp\u016Frn\u00E1 l\u00E9\u010Dba u pacient\u016F s refraktern\u00ED parci\u00E1ln\u00ED z\u00E1chvaty. Druhotn\u00FDm c\u00EDlem klinick\u00E9 studie je vyhodnotit bezpe\u010Dnost a sn\u00E1\u0161enlivost perampanel ve srovn\u00E1n\u00ED s placebem u osob s refraktern\u00ED parci\u00E1ln\u00ED z\u00E1chvaty."@cs . . "Hlavn\u00EDm c\u00EDlem klinick\u00E9 studie je zhodnotit \u00FA\u010Dinnost 3 d\u00E1vek perampanel (2 mg, 4 mg a 8 mg) ve srovn\u00E1n\u00ED s placebem dan\u00FD jako podp\u016Frn\u00E1 l\u00E9\u010Dba u pacient\u016F s refraktern\u00ED parci\u00E1ln\u00ED z\u00E1chvaty. Druhotn\u00FDm c\u00EDlem klinick\u00E9 studie je vyhodnotit bezpe\u010Dnost a sn\u00E1\u0161enlivost perampanel ve srovn\u00E1n\u00ED s placebem u osob s refraktern\u00ED parci\u00E1ln\u00ED z\u00E1chvaty." . "A Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizure"@en . "Refractory Partial Seizure"@en .